Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression

Fig. 4

GLI-1 is the critical component for positive feedback regulation of EZH2-integrin α11 axis

(A) Increased level of p-FAK in TAMR and ADR cells. *p < 0.05 compared to parental MCF-7 cells. (B) The effects of ITGA11, SUZ12, and EZH2 KD on FAK activity in TAMR and ADR cells. (C) Ifebemtinib, a FAK inhibitor, inhibits the nuclear level of GLI-1, but not of HIF-1α, GLI-1 and EZH2, in a concentration-dependent manner. *p < 0.05 compared to vehicle-treated control group. (D) ITGA11 KD inhibits both cytosolic and nuclear level of GLI-1. *p < 0.05 compared to siNT-transfected group

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us